Literature DB >> 21723219

Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment.

Jayant A Talwalkar1, Karen L Swanson, Michael J Krowka, James C Andrews, Patrick S Kamath.   

Abstract

BACKGROUND & AIMS: We documented the frequency of large spontaneous portosystemic shunts in patients with moderate or severe portopulmonary hypertension (POPH) and determined the association between large shunts and response to treatment.
METHODS: We performed a retrospective case-control study of data from patients with mild (mean pulmonary artery pressure [MPAP], 25-35 mm Hg; n = 18), moderate (MPAP, 35-50 mm Hg; n = 45), and severe POPH (MPAP, >50 mm Hg; n = 16). Data were compared with those from controls (normal echocardiography with estimated right ventricular systolic pressure, <35 mm Hg; n = 122). Spontaneous portosystemic shunts greater than 10 mm in diameter, identified by computed tomography or magnetic resonance, were classified as large. Response to treatment at 6 months was defined by right ventricular systolic pressure or MPAP as significant (<35 mm Hg), partial (35-50 mm Hg), or no response (>50 mm Hg).
RESULTS: The frequency of spontaneous shunts did not differ significantly between groups of subjects with severe (n = 14 of 16), moderate (n = 38 of 45), or mild POPH (n = 11 of 18) or normal echocardiograms (controls, n = 86 of 122) (P = .77). Large shunts were associated with severe (14 of 16) and moderate POPH (32 of 45), compared with mild POPH (6 of 18) or controls (30 of 122) (P < .01). In 13 patients with severe POPH, large shunts were associated with lack of response to treatment in 90% (8 of 9) or partial response in 50% (2 of 4). Among 27 patients with moderate POPH, large shunts were associated with no response to treatment in 13 of 19 (68%) and a partial response in 2 of 6 (33%).
CONCLUSIONS: Large spontaneous portosystemic shunts are associated significantly with moderate and severe POPH, and with lack of response to treatment.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723219     DOI: 10.1053/j.gastro.2011.06.053

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension.

Authors:  Hilary M DuBrock; Josanna M Rodriguez-Lopez; Barbara L LeVarge; Michael P Curry; Paul A VanderLaan; Zsuzsanna K Zsengeller; Elizabeth Pernicone; Ioana R Preston; Paul B Yu; Ivana Nikolic; Dihua Xu; Ravi I Thadhani; Richard N Channick; S Ananth Karumanchi
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

Review 2.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease.

Authors:  Michael J Krowka
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

Review 3.  Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.

Authors:  Juan Carlos Q Velez; George Therapondos; Luis A Juncos
Journal:  Nat Rev Nephrol       Date:  2019-11-13       Impact factor: 28.314

4.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.

Authors:  Kelley Weinfurtner; Kimberly Forde
Journal:  Curr Hepatol Rep       Date:  2020-07-11

Review 5.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

Review 6.  Management of portopulmonary hypertension: new perspectives.

Authors:  Luigi Mancuso; Francesca Scordato; Michela Pieri; Eliana Valerio; Andrea Mancuso
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 7.  Current Approach to the Diagnosis and Management of Portopulmonary Hypertension.

Authors:  Lynn A Fussner; Michael J Krowka
Journal:  Curr Gastroenterol Rep       Date:  2016-06

8.  A Case Report of Portopulmonary Hypertension Precipitated by Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Jasmine H Tatah; E Kenneth Weir; Kurt W Prins; Thenappan Thenappan
Journal:  Chest       Date:  2021-04-06       Impact factor: 9.410

9.  An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration.

Authors:  Hironori Tanaka; Yoshihito Saijo; Tetsu Tomonari; Takahiro Tanaka; Tatsuya Taniguchi; Shusuke Yagi; Koichi Okamoto; Hiroshi Miyamoto; Masahiro Sogabe; Yasushi Sato; Naoki Muguruma; Koichi Tsuneyama; Masataka Sata; Tetsuji Takayama
Journal:  Intern Med       Date:  2021-01-15       Impact factor: 1.271

10.  Living Donor Liver Transplantation in Biliary Atresia Children with Pulmonary Hypertension.

Authors:  Xiao-Yan Meng; Mi-Yuan Chen; Zhi-Ying Pan; Ye-Feng Lu; Wei Wei; Yu-Gang Lu
Journal:  Int J Med Sci       Date:  2019-08-14       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.